Biogen's stock slides on soft guidance and a decline in sales of MS drugs
The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...
‘Brilliant’: Celtic ready for 28-goal machine who is out to complete Glasgow set
When these two last met in Glasgow, Bayern won 2-1 in a Champions League group-stage encounter. Current Celtic captain Callum ...
Genmab A/S: Genmab Publishes 2024 Annual Report
Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...
Hosted on MSN16h
Celtic boss Brendan Rodgers eager for shot at “European royalty” with Bayern Munich
Celtic manager Brendan Rodgers is ready for a classic Champions League night vs. Bayern Munich. “We are very excited. It’s a ...
Celtic won when the Champions League changed – now they face a familiar challenge
Celtic won when the Champions League changed – now they face a familiar challenge - The Scottish champions play their first ...
Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None
We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...